Method for treating biological damage using a free-radial scavenger and interleukin-2
AssigneeCetus Oncology Corporation
InventorsRobert Zimmerman, Benedict J. Marafino, Jr.
Life of this patent
Estimating the term…
Abstract
Damage to cells, tissue and other body parts in a mammalian host may be treated by using a lymphokine or cytotoxin in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.
Claims17
A method for the therapeutic or prophylactic treatment of biological damage to a mammalian host in need of such treatment, said damage caused by free radical generation, which method comprises administering to the host therapeutically effective amounts of interleukin-2 from a mammalian species and at least one free radical scavenger, wherein said interleukin-2 and said free radical scavenger are administered to the host separately.
A composition comprising therapeutically effective amounts of interleukin-2 from a mammalian species and a free radical scavenger, wherein said free radical scavenger is buthionine sulfoximine.
An improved method for the treatment of biological damage in a host in need of such treatment, wherein said damage is caused by free radical generation, which method comprises administering to the host a therapeutically effective amount of a free radical scavenger in a first pharmaceutically acceptable carrier, and administering to the host a therapeutically effective amount of interleukin-2 in a second pharmaceutically acceptable carrier .
A unit dose comprising a first composition having a therapeutically effective amount of interleukin-2 and further comprising a second composition having a therapeutically effective amount of a free radical scavenger.
A composition comprising a free radical scavenger and interleukin-2, wherein the interleukin-2 is an IL-2 mutein.
Dependencies are inferred from the claim text.